tirzepatide and kidney disease ckd trial Chronic disease, complex conditions, advancing therapeutics: new hope and challenges Not currently a kidney therapy. – Renal effects of GLP-1 receptor

Rybelsus, by mimicking incretin hormones, enhances insulin production , decreases glucagon release, and slows stomach emptying, all of which contribute to potential weight loss

Hydrocarbon-stapled peptides: principles, practice, and progress: miniperspective

Use in the morning 1

Lilly's Triple Agonist, Retatrutide, Demonstrated Significant Reductions in A1C and Weight in First Phase 3 Trial for Treatment of Type 2 Diabetes

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial